U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11NO2.ClH
Molecular Weight 189.6396
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOPAMINE HYDROCHLORIDE

SMILES

c1cc(c(cc1CCN)O)O.Cl

InChI

InChIKey=CTENFNNZBMHDDG-UHFFFAOYSA-N
InChI=1S/C8H11NO2.ClH/c9-4-3-6-1-2-7(10)8(11)5-6;/h1-2,5,10-11H,3-4,9H2;1H

HIDE SMILES / InChI

Molecular Formula C8H11NO2
Molecular Weight 153.1787
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/21303898

Dopamine, a sympathomimetic amine vasopressor, is the naturally occurring immediate precursor of norepinephrine. G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension. Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure.

Originator

Curator's Comment:: reference retrieved from https://link.springer.com/chapter/10.1007%2F978-3-642-56051-4_2 | http://www.drugfuture.com/chemdata/dopamine.html

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DOPAMINE HYDROCHLORIDE

Approved Use

Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine’s direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine’s alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1712 ng/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOPAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2926 ng × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOPAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.6 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOPAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine.
2000
Cocaine self-administration behavior can be reduced or potentiated by the addition of specific dopamine concentrations in the nucleus accumbens and amygdala using in vivo microdialysis.
2000 Dec 5
Role of heme oxygenase-1 in the regulation of manganese superoxide dismutase gene expression in oxidatively-challenged astroglia.
2000 Oct
Comparison between the role of the neuronal and inducible nitric oxide synthase in methamphetamine-induced neurotoxicity and sensitization.
2000 Sep
Repeated adenosine pre-treatment potentiates the acute effect of methamphetamine in rats.
2000 Sep
Dopamine deficiency in mice.
2000 Sep
A hypertensive reaction induced by concurrent use of selegiline and dopamine.
2000 Sep
Haplotype evolution and linkage disequilibrium: A simulation study.
2001
Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
2001
The reverse transport of DA, what physiological significance?
2001 Feb
Pharmacology and behavioral pharmacology of the mesocortical dopamine system.
2001 Feb
Inhibition of a Gi-activated potassium channel (GIRK1/4) by the Gq-coupled m1 muscarinic acetylcholine receptor.
2001 Feb 23
Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro.
2001 Jan
Association analysis of a functional catechol-o-methyltransferase gene polymorphism in schizophrenic patients in Taiwan.
2001 Jan
Monoamine compounds in cerebrospinal fluid of healthy subjects punctured without preceding strict bed rest: a pilot study.
2001 Jan
The effects of water-odor preference conditioning in the preadolescent nucleus accumbens septi.
2001 Jan
In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
2001 Jan
Ascorbic acid increases the yield of dopaminergic neurons derived from basic fibroblast growth factor expanded mesencephalic precursors.
2001 Jan
Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum.
2001 Jan
N-methyl-D-aspartate receptors mediating hippocampal noradrenaline and striatal dopamine release display differential sensitivity to quinolinic acid, the HIV-1 envelope protein gp120, external pH and protein kinase C inhibition.
2001 Jan
Neurotrophic and neurotoxic effects of nitric oxide on fetal midbrain cultures.
2001 Jan
Radiosynthesis of [123I]betaCIT, a selective ligand for the study of the dopaminergic and serotoninergic systems in human brain.
2001 Jan
D2 receptor imaging in neonates using I-123 iodobenzamide brain SPECT.
2001 Jan
Investigation of non-linear properties of multichannel EEG in the early stages of Parkinson's disease.
2001 Jan
Characterization of acute inhibition of Na/H exchanger NHE-3 by dopamine in opossum kidney cells.
2001 Jan
Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase.
2001 Jan
Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine.
2001 Jan
Ethanol acts synergistically with a D2 dopamine agonist to cause translocation of protein kinase C.
2001 Jan
Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent.
2001 Jan
Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence.
2001 Jan
Pharmacological agents for the treatment of urinary incontinence due to overactive bladder.
2001 Jan
Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.
2001 Jan
A study of the binding requirements of calyculin A and dephosphonocalyculin A with PP1, development of a molecular recognition model for the binding interactions of the okadaic acid class of compounds with PP1.
2001 Jan
Fatty acid derivatives of clozapine: prolonged antidopaminergic activity of docosahexaenoylclozapine in the rat.
2001 Jan
Noninvasive assessment of aromatic L-amino acid decarboxylase activity in aging rhesus monkey brain in vivo.
2001 Jan
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
2001 Jan
Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
2001 Jan
Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat.
2001 Jan
Iboga interactions with psychomotor stimulants: panacea in the paradox?
2001 Jan
Regulation by the medial amygdala of copulation and medial preoptic dopamine release.
2001 Jan 1
Motivational effects of ethanol in DARPP-32 knock-out mice.
2001 Jan 1
Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists.
2001 Jan 1
Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.
2001 Jan 1
Expression of calbindin D28K in the dopaminergic mesotelencephalic system in embryonic and fetal human brain.
2001 Jan 1
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
2001 Jan 12
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1.
2001 Jan 12
Striatal preprotachykinin mRNA levels are regulated by stimulatory agents and dopamine D1 receptor manipulation in rodent organotypic slice cultures.
2001 Jan 5
Autoregulation of dopamine synthesis in subregions of the rat nucleus accumbens.
2001 Jan 5
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
2001 Jan 5
Gyroxin fails to modify in vitro release of labelled dopamine and acetylcholine from rat and mouse striatal tissue.
2001 Jun
Patents

Sample Use Guides

Rate of Administration – Dopamine Hydrochloride Injection, USP after dilution, is administered intravenously by infusion via a suitable I.V. catheter or needle. When administering Dopamine Hydrochloride (or any potent medication) by continuous intravenous infusion, it is advisable to use a precision volume control I.V. set. Each patient must be individually titrated to the desired hemodynamic or renal response to dopamine.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:53:08 UTC 2021
Edited
by admin
on Fri Jun 25 20:53:08 UTC 2021
Record UNII
7L3E358N9L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOPAMINE HYDROCHLORIDE
EP   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN  
Official Name English
DOPAMINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
4-(2-AMINOETHYL)PYROCATECHOL HYDROCHLORIDE
Systematic Name English
INOTROPIN
Common Name English
TENSAMIN
Common Name English
DOPAMINE HYDROCHLORIDE [MI]
Common Name English
CARDIOSTERIL
Common Name English
DOPAMINE HYDROCHLORIDE [MART.]
Common Name English
DOPAMINE HYDROCHLORIDE [WHO-IP]
Common Name English
DOPAMINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
DOPAMINE HYDROCHLORIDE [USP-RS]
Common Name English
DOPAMINE HYDROCHLORIDE [USAN]
Common Name English
DOPAMINE HYDROCHLORIDE [VANDF]
Common Name English
DOPAMINE HCL
Common Name English
1,2-BENZENEDIOL, 4-(2-AMINOETHYL)-, HYDROCHLORIDE
Systematic Name English
INTROPIN
Brand Name English
DOPAMINE HYDROCHLORIDE [JAN]
Common Name English
DOPAMINE HYDROCHLORIDE [WHO-DD]
Common Name English
ASL-279
Code English
NSC-169105
Code English
DOPAMINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
DOPAMINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29709
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
FDA ORPHAN DRUG 578817
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
Code System Code Type Description
PUBCHEM
65340
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL59
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
DRUG BANK
DBSALT000508
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
NCI_THESAURUS
C455
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
EVMPD
SUB01818MIG
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
EPA CompTox
62-31-7
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
RXCUI
82010
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY RxNorm
ECHA (EC/EINECS)
200-527-8
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
CAS
62-31-7
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
USP_CATALOG
1225204
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY USP-RS
WHO INTERNATIONAL PHARMACOPEIA
DOPAMINE HYDROCHLORIDE
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY Description: Colourless crystals or a white or almost white, crystalline powder; odourless.Solubility: Freely soluble in water; soluble in methanol R; practically insoluble in ether R and toluene R.Category: Cardiovascular drug; sympathomimetic.Storage: Dopamine hydrochloride should be kept in a well-closed container, protected from light.Requirements: Definition. Dopamine hydrochloride contains not less than 98.0% and not more than 101.0% of C8H11NO2,HCl, calculated withreference to the dried substance.
MERCK INDEX
M4740
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY Merck Index
FDA UNII
7L3E358N9L
Created by admin on Fri Jun 25 20:53:08 UTC 2021 , Edited by admin on Fri Jun 25 20:53:08 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
Related Record Type Details
ACTIVE MOIETY